Equities Analysts Issue Forecasts for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Viridian Therapeutics in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($1.36) EPS and FY2028 earnings at $1.34 EPS.

VRDN has been the topic of a number of other research reports. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Royal Bank of Canada upped their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. TD Cowen began coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Monday, December 16th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Trading Up 1.6 %

Shares of VRDN opened at $19.21 on Wednesday. The business’s 50-day moving average price is $19.43 and its 200 day moving average price is $19.39. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics has a 1-year low of $11.40 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in Viridian Therapeutics by 16.8% during the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after acquiring an additional 1,610,130 shares during the period. Novo Holdings A S raised its position in shares of Viridian Therapeutics by 19.3% during the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock valued at $54,259,000 after buying an additional 385,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Viridian Therapeutics by 5.8% in the third quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock valued at $33,979,000 after buying an additional 81,951 shares during the period. Great Point Partners LLC grew its position in Viridian Therapeutics by 50.0% during the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock worth $17,062,000 after buying an additional 250,000 shares in the last quarter. Finally, Walleye Capital LLC increased its stake in Viridian Therapeutics by 30.1% during the third quarter. Walleye Capital LLC now owns 560,007 shares of the company’s stock valued at $12,740,000 after acquiring an additional 129,411 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.